142 related articles for article (PubMed ID: 38330545)
41. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
42. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
[TBL] [Abstract][Full Text] [Related]
43. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.
Zhao C; Chu Y; Liang Z; Zhang B; Wang X; Jing X; Hao M; Wang Y; An J; Zhang X; Sun L; Chen J
BMC Immunol; 2019 Sep; 20(1):32. PubMed ID: 31484501
[TBL] [Abstract][Full Text] [Related]
44. Autoimmune thyroid disease is associated with a diagnosis of secondary Sjögren's syndrome in familial systemic lupus.
Scofield RH; Bruner GR; Harley JB; Namjou B
Ann Rheum Dis; 2007 Mar; 66(3):410-3. PubMed ID: 16984944
[TBL] [Abstract][Full Text] [Related]
45. Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus.
Xie JH; Zhang Y; Loubeau M; Mangan P; Heimrich E; Tovar C; Zhou X; Madia P; Doyle M; Dudhgaonkar S; Rudra A; Subramani S; Young J; Salter-Cid L; Malek TR; Struthers M
J Immunol; 2021 Jul; 207(1):34-43. PubMed ID: 34108258
[TBL] [Abstract][Full Text] [Related]
46. [Biological therapy of arthritis and systemic autoimmune diseases].
Tamási L; Szekanecz Z
Orv Hetil; 2007 Apr; 148 Suppl 1():63-70. PubMed ID: 17430797
[TBL] [Abstract][Full Text] [Related]
47. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
48. Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial.
Wang J; Zhang SX; Chang JS; Cheng T; Jiang XJ; Su QY; Zhang JQ; Luo J; Li XF
Front Immunol; 2022; 13():947341. PubMed ID: 36524114
[TBL] [Abstract][Full Text] [Related]
49. Emerging role of interleukin-22 in autoimmune diseases.
Pan HF; Li XP; Zheng SG; Ye DQ
Cytokine Growth Factor Rev; 2013 Feb; 24(1):51-7. PubMed ID: 22906768
[TBL] [Abstract][Full Text] [Related]
50. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis.
Buitrago-Molina LE; Pietrek J; Noyan F; Schlue J; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
J Autoimmun; 2021 Feb; 117():102591. PubMed ID: 33387980
[TBL] [Abstract][Full Text] [Related]
51. [New directions of pharmacotherapy of immune - inflammatory rheumatic diseases].
Nasonov EL
Ter Arkh; 2019 Aug; 91(8):98-107. PubMed ID: 32598760
[TBL] [Abstract][Full Text] [Related]
52. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
Jeffery HC; Jeffery LE; Lutz P; Corrigan M; Webb GJ; Hirschfield GM; Adams DH; Oo YH
Clin Exp Immunol; 2017 Jun; 188(3):394-411. PubMed ID: 28176332
[TBL] [Abstract][Full Text] [Related]
53. A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases.
Simon Q; Grasseau A; Boudigou M; Le Pottier L; Bettachioli E; Cornec D; Rouvière B; Jamin C; Le Lann L; ; ; Borghi MO; Aguilar-Quesada R; Renaudineau Y; Alarcón-Riquelme ME; Pers JO; Hillion S
Arthritis Rheumatol; 2021 Aug; 73(8):1550-1561. PubMed ID: 33605069
[TBL] [Abstract][Full Text] [Related]
54. Evaluating the risk of ischemic stroke at a young age in patients with autoimmune inflammatory rheumatic diseases: a population-based cohort study in Taiwan.
Huang YC; Lai EC; Liao TC; Weng MY
Front Immunol; 2024; 15():1272557. PubMed ID: 38404587
[TBL] [Abstract][Full Text] [Related]
55. Nationwide analysis of neuromyelitis optica in systemic lupus erythematosus and Sjogren's syndrome.
Sami F; Sami SA; Manadan AM; Arora S
Clin Rheumatol; 2024 Jan; 43(1):59-65. PubMed ID: 37980305
[TBL] [Abstract][Full Text] [Related]
56. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
Bell CJ; Sun Y; Nowak UM; Clark J; Howlett S; Pekalski ML; Yang X; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Umana P; Klein C; Hosse RJ; Wicker LS; Peterson LB
J Autoimmun; 2015 Jan; 56():66-80. PubMed ID: 25457307
[TBL] [Abstract][Full Text] [Related]
57. Genetic variants of chemokine receptor CCR7 in patients with systemic lupus erythematosus, Sjogren's syndrome and systemic sclerosis.
Kahlmann D; Davalos-Misslitz AC; Ohl L; Stanke F; Witte T; Förster R
BMC Genet; 2007 Jun; 8():33. PubMed ID: 17587445
[TBL] [Abstract][Full Text] [Related]
58. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
59. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
Narain S; Berman N; Furie R
Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
[TBL] [Abstract][Full Text] [Related]
60. Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.
Su Q; Wang X; Li Y; Zhang J; Bai C; Wang X; Yang L; Zhang J; Zhang SX
Rheumatol Ther; 2024 Feb; 11(1):79-96. PubMed ID: 37980696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
